|
| 37503312 | Concurrent chemotherapy with partial breast irradiation in triple negative breast cancer patients may improve disease control compared with sequential therapy. | | 2023 |
| 36369671 | Evaluating potential overuse of surveillance care in cancer survivors. | Cancer Med | 2023 |
| 36130057 | Improving biobehavioral health in younger breast cancer survivors: Pathways to Wellness trial secondary outcomes. | Journal of the National Cancer Institute | 2023 |
| 36446052 | Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets. | Journal of Clinical Oncology | 2023 |
| 37652539 | Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). | J Nucl Med | 2023 |
| 38095878 | Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. | | 2023 |
| 37556775 | Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. | J Clin Oncol | 2023 |
| 37406455 | Flashback Foreword: Multigene Predictor for Chemotherapy Response in Breast Cancer. | | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37405703 | Physicians' Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care. | | 2023 |
| 36898259 | Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials. | | 2023 |
| 37269905 | ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. | Ann Oncol | 2023 |
| 36945501 | Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. | medRxiv | 2023 |
| 37195235 | A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. | Clin Cancer Res | 2023 |
| 37310797 | Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG). | Oncologist | 2023 |
| 36473142 | Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer Treatment. | JCO Oncol Pract | 2023 |
| 37303228 | Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. | | 2023 |
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 36681001 | Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. | | 2023 |
| 36534524 | Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. | Clin Cancer Res | 2023 |
| 36529890 | Racial and ethnic disparities in mortality among breast cancer survivors after a second malignancy. | | 2023 |
| 34874182 | Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). | J Clin Oncol | 2022 |
| 36046124 | Development of an automated liquid biopsy assay for methylated markers in advanced breast cancer. | Cancer Res Commun | 2022 |
| 35704278 | Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. | Oncologist | 2022 |
| 35449210 | Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. | npj Breast Cancer | 2022 |
| 35439025 | Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. | J Clin Oncol | 2022 |
| 36215065 | Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials. | Oncologist | 2022 |
| 35377771 | Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. | JCO Oncol Pract | 2022 |
| 35735435 | Weight Gain after Hormone Receptor-Positive Breast Cancer. | Current Oncology | 2022 |
| 36201176 | Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. | JAMA Oncol | 2022 |
| 35352140 | Investigating the impact of the COVID-19 pandemic on breast cancer clinicians' communication about sexual health. | Support Care Cancer | 2022 |
| 36450763 | Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). | NPJ Breast Cancer | 2022 |
| 34296383 | Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trial. | J Cancer Surviv | 2022 |
| 34302474 | Simplifying Survivorship Care Planning: A Randomized Controlled Trial Comparing 3 Care Plan Delivery Approaches. | J Natl Cancer Inst | 2022 |
| 35173164 | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. | NPJ Breast Cancer | 2022 |
| 35136076 | Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer. | npj Breast Cancer | 2022 |
| 35113131 | ERBB2-Low Breast Cancer-Is It a Fact or Fiction, and Do We Have the Right Assay? | JAMA Oncology | 2022 |
| 34813345 | Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment. | Journal of Clinical Oncology | 2022 |
| 34586509 | Late effects in a high-risk population of breast cancer survivors. | Supportive Care in Cancer | 2022 |
| 35074264 | Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. | Clin Breast Cancer | 2022 |
| 35120494 | Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates. | BMC Cancer | 2022 |
| 34543146 | Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). | Radiology | 2021 |
| 34077270 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. | J Clin Oncol | 2021 |
| 34120223 | Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). | Breast Cancer Res Treat | 2021 |
| 33691275 | Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. | Journal of the National Comprehensive Cancer Network : JNCCN | 2021 |
| 33579966 | A randomized intervention involving family to improve communication in breast cancer care. | npj Breast Cancer | 2021 |
| 34164605 | Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. | JNCI Cancer Spectrum | 2021 |
| 33999652 | Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. | J Clin Oncol | 2021 |
| 33460574 | Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. | Lancet Oncol | 2021 |
| 34092112 | Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. | J Clin Oncol | 2021 |